Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes

Hormone and Metabolic Research

Volumn 40, Issue 11, 2008, Pages 801-805

  Zhu, J ^a,c   Schott, M ^b   Liu, R ^a   Liu, C ^a,b   Shen, B ^a   Wang, Q ^a   Mao, X ^a   Xu, K ^a   Wu, X ^a   Schinner, S ^b   Papewalis, C ^b   Scherbaum, W A ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Intensive glycemic control; Type 2 diabetes mellitus; Visfatin

Indexed keywords

HEMOGLOBIN A1C; VISFATIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRIC OXIDE; TRIGLYCERIDES;

EID: 57149085712     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082040     Document Type: Article

References (28)

1. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa V, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
2. Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue-an update. Horm Metab Res 2007; 39: 314-321
3. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Plasma visfatin concentrations and fat epotspecific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
4. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
5. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, Smith U. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91: 1181-1184
6. Arner P. Visfatin: a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 28-30
7. Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from the PIOSTAT study. Horm Metab Res 2007; 39: 764-768
8. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914
9. López-Bermejo A, Chico-Julià B, Fernàndez- Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernández-Real JM. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875
10. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-548
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
12. Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, Han JF, Zhao Y, Li G, Luo M. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 2006; 23: 967-973
13. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007; 30: 318-324
14. Mills GW, Avery PJ, MacCarthy MI, Hattersley AT, Levy JC, Hitman GA, Sampson M, Walker M. Heritability estimates for β cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia 2004; 47: 732-738
15. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581
16. Böttcher Y, Teupser D, Enigk B, Berndt J, Klöting N, Schön MR, Thiery J, Blüher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat depot specific mRNA expression in humans. J Clin Endocrinol Metab 2006; 91: 2725-2731
17. Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, Papasteriades C, Raptis SA. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007; 39: 758-763
18. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003; 544: 74-78
19. Samal B, Sun Y, Stearns G, Xie C, Suggs S, MacNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor. Mol Cell Biol 1994; 14: 1431-1437
20. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327
21. Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 2005; 70: 142-151
22. +-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 2005; 97: 25-34
23. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 3225-3234
24. Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007; 75: 327-332
25. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27: 2597-2602
26. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005; 185: R1-R8
27. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005; 289: E586-E590
28. Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, Hansen-Algenstaedt N, Beil FU, Algenstaedt P. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007; 39: 250-255